Last reviewed · How we verify
AD-101 45mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
AD-101 45mg (AD-101 45mg) — Addpharma Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AD-101 45mg TARGET | AD-101 45mg | Addpharma Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AD-101 45mg CI watch — RSS
- AD-101 45mg CI watch — Atom
- AD-101 45mg CI watch — JSON
- AD-101 45mg alone — RSS
Cite this brief
Drug Landscape (2026). AD-101 45mg — Competitive Intelligence Brief. https://druglandscape.com/ci/ad-101-45mg. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab